Sanofi stock may face pressure as amlitelimab efficacy falls below expectations
Sanofi's stock is likely to experience pressure as the efficacy of its drug amlitelimab has fallen below market expectations.
WPN Brief
Sanofi's stock is likely to experience pressure as the efficacy of its drug amlitelimab has fallen below market expectations.
Ask WPN AI